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Abstract 
This mini-review focuses on the processes and consequences of protein folding and misfolding. The 
latter process often leads to protein aggregation and precipitation with the aggregates adopting either 
highly ordered (amyloid fibril) or disordered (amorphous) forms. In particular, the amyloid fibril is 
discussed because this form has gained considerable notoriety due to its close links to a variety of 
debilitating diseases including Alzheimer's, Parkinson's, Huntington's, and Creutzfeldt-Jakob diseases, 
and type-II diabetes. In each of these diseases a different protein forms fibrils, yet the fibrils formed have 
a very similar structure. The mechanism by which fibrils form, fibril structure, and the cytotoxicity 
associated with fibril formation are discussed. The generic nature of amyloid fibril structure suggests that 
a common target may be accessible to treat amyloid fibril-associated diseases. As such, the ability of 
some molecules, for example, the small heat-shock family of molecular chaperone proteins, to inhibit 
fibril formation is of interest due to their therapeutic potential. 
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SHOWCASE ON RESEARCH
The dogma of protein folding, based largely on the work 
of Christian Anfinsen some 50 years ago (1), is that all the 
information required for a protein to fold into its proper 
three-dimensional structure (and hence functional form) is 
contained within its amino acid sequence. However, even 
if, following translation, a protein successfully attains its 
biologically active state, this often does not herald the 
end-point of its folding/unfolding life. Many proteins go 
through cycles of unfolding and refolding due to a variety 
of factors that include transport across a membrane, 
cellular secretion, or exposure to stress conditions (e.g. 
changes in pH, temperature). As a result, the chance for 
protein misfolding is relatively high and so the whole 
process must be tightly regulated to ensure that it 
functions smoothly. The failure of a protein to fold 
correctly can have serious consequences; it is now 
recognised that protein misfolding lies at the very heart of 
a number of our most debilitating diseases (Table 1). This 
review will focus on the process of protein misfolding, 
highlighting its consequences (i.e. protein aggregation and 
precipitation) and the forms that these misfolded protein 
aggregates may take (ordered vs disordered). In 
particular, the highly ordered protein aggregate known as 
an amyloid fibril will be discussed since this form has 
gained considerable notoriety due to its links to most of 
the aforementioned diseases.
Proteins Can Aggregate Through Two Distinct 
Mechanisms
During and immediately following its translation on the 
ribosome, the newly formed protein meets the first major 
hurdle of its life: to fold into the conformation it requires 
in order to fulfil its raison d'etre. This, in itself, is not a 
trivial task since the number of theoretical interactions 
between each of its amino acid side chains far exceeds the 
total number of protein molecules within the cell and 
establishing the correct interactions is vital if the protein is 
to fold correctly. In addition, the protein must fold within 
the crowded environment of the cell, in which the 
intracellular concentration of protein can be as high as 350 
mg/mL (2), and so the chance of it making inappropriate 
contacts with other proteins is very high. Yet, the driving 
force that pushes the protein to attain its lowest free 
energy state (i.e. its native conformation in the majority of 
cases) ensures that most proteins fold spontaneously and 
rapidly (in the order of micro- to milliseconds) and, more 
often than not, folding occurs without problems (3). 
Interestingly, some proteins never attain a defined 
conformation, and instead, in their biologically active state, 
remain intrinsically disordered, i.e. they have ill-defined 
secondary and tertiary structures in their native state.
For other proteins, folding does not occur unassisted and 
instead the whole folding process is overseen by a 
number of auxiliary proteins, such as catalysts and 
molecular chaperones, which ensure a high degree of 
folding fidelity. Whilst occurring quickly, the folding 
pathway of a protein typically does not occur in one step 
but instead proceeds through a number of intermediately 
folded states (each with lower energy than the unfolded 
protein) in which a few key initial contacts are established 
that are crucial in directing the correct protein structure. 
Subsequent hydrogen bonding and hydrophobic 
interactions enable the protein to attain its fully folded 
form (Fig. 1). The folding pathway is reversible. The 
folded protein, when required to or when subjected to 
stress (that causes the disruptions to hydrogen bonding 
and hydrophobic interactions between some side chains), 
partially unfolds to its intermediately folded state(s).
Table 1. Some known diseases associated with 
amyloid fibril formation and the main protein 
component of the aggregates formed.
Disease	 Main protein
Alzheimer's disease	 Aβ peptides, Tau
Frontal-temporal dementias	 Tau
Parkinson's disease	 α-Synuclein




Type 2 diabetes	 Amylin
Senile systemic amyloidosis	 Transthyretin
Familial amyloid polyneuropathy I	 Transthyretin
Familial amyloid polyneuropathy III	 Apolipoprotein AI
Haemodialysis-related amyloidosis	 β2-Microglobulin
Injection-localised amyloidosis	 Insulin
Hereditary non-neuropathic systemic	 Lysozyme
amyloidosis
Spinocerebellar ataxias	 Ataxins
Spinocerebellar ataxia 17	 TATA-box binding
	 protein
Primary systemic amyloidosis	 Ig light chains
Secondary systemic amyloidosis	 Serum amyloid A
Amyotrophic lateral sclerosis	 Superoxide
	 dismutase I
Medullary carcinoma of the thyroid	 Calcitonin
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Despite the number of checkpoints that exist to ensure 
proper folding of proteins, problems can arise due to 
undesirable interactions during folding. The main cause 
of this is the persistence of intermediately folded states 
of the protein on the folding pathway, a process that can 
be exacerbated by mutation and/or cellular stress. These 
i n t e r m e d i a t e  s t a t e s ,  w h i c h  e x p o s e  i n c r e a s e d  
hydrophobicity to solution, are prone to self-association, 
leading to subsequent aggregation and precipitation. 
When this occurs, the protein leaves the folding pathway 
and enters the protein off-folding pathway, which is 
relatively slow (in the order of seconds) and driven 
primarily by the hydrophobic interactions between 
intermediately folded states (Fig. 1). The off-folding 
pathway comprises two distinct routes (into either 
disordered or ordered aggregates) by which aggregation 
of the protein may proceed. Determining which off-
folding pathway predominates is often governed by the 
speed at which protein unfolding and aggregation 
occurs, its amino acid sequence and the nature of the 
intermediates that are formed.
A disordered aggregation mechanism results from the 
rapid unfolding and subsequent aggregation of 
intermediately folded proteins, in which individual 
monomers add to the growing clump of aggregated 
protein through a random process. This leads to the 
formation of amorphous aggregates which eventually 
become so large that they form an insoluble precipitate. 
This type of aggregation is most often the bane of 
protein researchers as it is the underlying mechanism 
behind inclusion body formation in bacterial cells during 
recombinant protein expression and is also responsible 
for proteins 'falling out' of solution when changing 
buffer conditions. With regards to inclusion body 
formation,  the huge amount of  protein formed 
overwhelms the cell's ability to properly fold the newly 
expressed protein and so the misfolded protein 
aggregates and precipitates. However, under normal 
circumstances in the cell, amorphous aggregation is 
often not of major concern since it is well equipped to 
detect their formation and dispose of them into the 
proteasomal 'dustbin' before they precipitate. 
Amyloid Fibrils are Formed Through an Ordered 
Aggregation Mechanism
In contrast to the formation of amorphous (disordered) 
clumps of protein, aggregation may occur more slowly 
through a highly ordered nucleation-dependent 
mechanism in which partially folded forms of the 
protein associate together to form a stable nucleus (the 
rate determining step). This nucleus then acts as a 
template to sequester other intermediates to add to the 
growing thread of aggregated protein (protofibril). The 
sequential addition of partially folded intermediates to 
the ends of the chain leads to the formation of a highly 
structured, insoluble form of protein known as an 
amyloid fibril (Fig. 2A,B). Such a mechanism explains 
the observed kinetics of fibril formation as monitored 
using amyloid-binding dyes such as thioflavin T or 
Congo red (Fig. 2C). Both the length of the lag phase 
and the rate of elongation are highly dependent on the 
protein concentration through their reliance on the 
concentration of partially folded intermediates present at 
any given time (4).  
Amyloid fibril formation is often associated with 
disease and is believed to be causative, or at least linked, 
to disease onset and progression (5-7). However, the 
disease related proteins found as fibrillar aggregates in 
vivo share no obvious sequence or structural similarities 
in their native state (Table 1). Moreover, the amyloid 
fibril conformation has been found to be accessible to a 
diverse range of proteins, such that it is now thought to 
be a generic structural form that all proteins can adopt 
given appropriate conditions (8).
The Generic Structure of Amyloid Fibrils
The characterisation of amyloid fibril formation by 
proteins in vitro  has, to date, largely focused on 
biophysical studies to determine the structure of the 
fibril, and biochemical studies into the mechanism and 
kinetics of the process. Through such techniques as X-
ray fibre diffraction, cryo-electron microscopy and solid 
state NMR spectroscopy we now have a detailed 
understanding of the core architecture of individual 
fibrils. All fibrils share a characteristic 'cross β-sheet 
array', so called since individual fibrils are made up of 
sheets of β-strands which lie perpendicular to the core 
axis of the fibril and which stack together to form an 
Fig. 1. The protein on-folding pathway and the off-
folding pathways that lead to protein aggregation. An 
unfolded protein folds to its native state via the 
formation of partially folded intermediates. This 
process is fast and reversible. However, under 
conditions in which the partially folded intermediates 
persist (e.g. during times of cellular stress or due to 
mutation), they can mutually associate via exposed 
hydrophobic regions that are normally buried into the 
core of the protein in its native state. When this 
occurs, the intermediates aggregate via either a 
disordered or ordered mechanism, leading to the 
formation of amorphous precipitates or amyloid 
fibrils, respectively.
















individual filament (Fig. 2B). This results 
in a characteristic cross formed by the 
meridional (~ 4.7 Å) and equatorial (~ 9-
11 Å) reflections in X-ray diffraction 
studies (Fig. 2D), which represent the 
hydrogen bonding distance between 
adjacent β-strands that make up a β-sheet 
and the distance between β-sheets, 
respectively. The presence of this 'cross β-
sheet array' as the underlying architecture 
of fibrils observed by techniques such as 
transmission electron microscopy and 
atomic force microscopy is now seen as 
the diagnostic test for the presence of 
amyloid f ibri ls .  Mature f ibri ls  are 
commonly composed of  two to six  
protofilaments that plait together into 
rope-like fibres, 5-10 nm in diameter and 
up to a few microns in length. The fibrils 
formed are often unbranched, extremely 
stable and resistant to degradation by 
proteases  and denaturants .  These  
properties are thought to be responsible 
for the difficulty the cell has in eliminating 
fibrils once they have been formed. 
The overall stability of the fibril is 
achieved by intermolecular hydrogen 
bonds involving backbone atoms between 
the amide and carbonyl groups of the 
polypeptide main chain; the peptide 
backbone being common to all proteins is 
therefore thought to dictate why all fibrils 
share a common morphology. It also 
explains why very structurally diverse 
proteins are able to adopt the amyloid-
fibril conformation, including those which 
are predominately α-helical in their native 
state (9-11). However, the propensity for a 
given peptide or protein to form fibrils 
can vary dramatically with sequence and 
some regions of a protein may be more 
prone to aggregation than others. Thus, 
whilst it may be true that all proteins are 
c a p a b l e  o f  f o r m i n g  f i b r i l s ,  t h e  
composition and amino acid sequence of 
a protein profoundly affects its propensity 
to adopt such structures. Moreover, the 
tendency of a polypeptide chain to 
aggregate, rather than fold correctly, 
depends on a number of intrinsic factors, 
including the propensity for it to form β-
strands, its hydrophobicity and its overall 
net charge (12,13). The specific link 
between these physiochemical properties 
of constituent amino acid residues and 
their aggregation propensities has led to 
t h e  d e v e l o p m e n t  o f  a  n u m b e r  o f  
predictive algorithms for amyloidogenic 
regions of proteins that are based solely 
on their amino acid sequences (14,15).
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Fig. 2. Monitoring the formation of amyloid fibrils and their generic 
core architecture.
A. The typical structure of amyloid fibrils as viewed by transmission 
electron microscopy, showing them as long, unbranched, rope-like fibres. 
Scale bar is 1 µm.
B. In the left panel, a magnified view of a fibril highlighting its internal 
protofilament substructure (scale bar is 200 nm). In the right panel, a 
schematic view of an amyloid fibril formed from insulin. This model shows 
the core structure of each filament, i.e. the typical cross β-sheet array formed 
from sheets of β-strands lying perpendicular to the axis of the fibril and the 
aligning of these β-sheets into individual filaments (reproduced from (26)).
C. Monitoring amyloid fibril formation via the change in fluorescence of 
the amyloid-binding dye thioflavin T upon its binding to the fibril. The 
kinetics of fibril formation include a lag phase, elongation phase and 
plateau phase and the rate of fibril formation increases with increasing 
concentrations of protein.
D. X-ray fibre diffraction of amyloid fibrils showing the diagnostic 
meridional and equatorial reflections which form the 'cross β-sheet' pattern.
E. The nucleation-dependent model of amyloid fibril formation. Fibril 
formation commences with the unfolding of a native protein, forming a 
pool of partially folded intermediates, a process that is reversible. The 
partially folded intermediates are able to associate with each other until 
they reach a critical size/mass at which a stable nucleus is formed. The 
formation of this nucleus from the partially folded intermediates is slow 
and rate-limiting in the overall process of fibril formation (lag phase). 
Fibril elongation then proceeds via the addition of intermediates to the 
growing nucleus. The mechanism also explains how seeding the reaction 
increases the reaction rate and decreases the lag phase since addition of 
preformed fibrils overcomes the time required to form nuclei.
Toxic Protein Aggregation and its Prevention
In each of the amyloid diseases, and there have now 
been at least 20 which have been identified, the fibrils that 
are formed are primarily associated with one protein or 
protein fragment, e.g. the amyloid-β peptides Aβ1-40 and 
Aβ1-42 in Alzheimer's disease, α-synuclein in Parkinson's 
disease and the prion protein in the transmissible 
spongiform encephalopathies (see Table 1). In many of 
these diseases, the fibrils then self assemble into tangled 
plaques, the hallmark of most neurodegenerative 
conditions and the site at which the toxic effect of fibril 
formation is most evident. However, the cytotoxicity 
associated with amyloid formation is not restricted to 
disease-related proteins; fibrils and their precursors 
formed from non-disease related proteins, such as the 
SH3 domain from bovine phosphatidylinositol 3' kinase 
and the N-terminal domain of Escherichia coli HypF 
protein (HypF-N), show similar levels of cytotoxocity (16). 
There remains considerable debate as to the species 
responsible for the cytotoxicity of amyloid fibrils. 
A l t h o u g h  t h e r e  a r e  o b v i o u s  n e g a t i v e  e f f e c t s  o f  
extracellular amyloid plaque deposition, recent studies 
have suggested that it is primarily the soluble, pre-
fibrillar dimers, trimers or other such oligomers, which 
are formed during the early stages of fibril formation, that 
are responsible for cell toxicity in neurodegenerative 
diseases such as Alzheimer's and Parkinson's disease 
(5,7). Others have indicated that the mature fibril can also 
be toxic (17,18) and, in fact, the cytotoxic species may 
vary depending on the precursor fibril-forming protein. 
A wide variety of biochemical changes have been 
reported following exposure of neuronal cells in culture 
to amyloid fibrils or their precursors. It is not clear how 
the species formed during amyloid fibril assembly cause 
cell death, and indeed whether the mechanism behind the 
toxicity is the same for all amyloid fibril-forming proteins. 
A number of hypotheses have been proposed, for 
example, that a soluble precursor forms a pore-like 
structure in cell membranes (the amyloid channel or 
amyloid pore) and this culminates in neuronal death by 
unregulated membrane permeabilisation (19,20). Others 
have suggested that the toxicity of prefibrillar amyloid 
species is due to the production of reactive oxygen 
species (e.g. hydrogen peroxide) by the aggregating target 
protein itself, which are generated as a consequence of the 
fibril-forming process (21). In support of this, cells can be 
protected against amyloid aggregate toxicity by treatment 
with antioxidants such as tocopherol, lipoic acid and 
reduced glutathione. An advantage of some of these anti-
oxidant compounds is that they also are able to inhibit the 
process of fibril formation (22), most likely due to a direct 
effect on the hydrophobic association steps required for 
nuclei formation. Thus, these anti-oxidants or derivatives 
thereof are promising drug targets due to their combined 
anti-oxidant and anti-amyloidogenic activities.   
Other well-described inhibitors of protein aggregation, 
and therefore amyloid fibril formation, are molecular 
chaperone proteins, in particular, intracellular small heat 
shock proteins (sHsps) and extracellular clusterin (23). 
The sHsps are a ubiquitous group of proteins that are the 
first line of defence a cell has against physiological stress 
conditions that promote protein aggregation. The 
chaperone act ion of  sHsps does not  require  ATP 
hydrolysis and therefore they can be utilised by the cell 
under conditions in which energy levels are low, e.g. 
during cellular stress. sHsps seem to employ two distinct 
mechanisms to prevent protein aggregation. In some 
instances, they bind to long-lived, partially structured 
intermediates, primarily though hydrophobic interactions, 
to form a stable, soluble, chaperone-target protein 
complex (i.e. a 'reservoir of intermediates'). Neither sHsps 
or clusterin have the capability of refolding the target 
protein but instead act to maintain its solubility until 
cellular conditions allow them to be picked up and acted 
upon by other chaperones, such as Hsp70 and Hsp60, that 
use ATP hydrolysis to refold the protein. In other cases, 
sHsps may only transiently interact with the target to 
stabilise it and allow it to refold back to its native state 
upon release .  We have found the lat ter  to  be  the 
mechanism utilised by the sHsp, α-crystallin, against fibril 
formation by apolipoprotein C-II (24). 
No matter which mechanism is utilised, sHsps and 
clusterin are ideally suited to prevent amyloid fibril 
formation since they act very efficiently against slowly 
aggregating target proteins, a process that governs the 
ordered aggregation mechanism that leads to fibril 
formation. Interestingly, the expression of sHsps and 
c l u s t e r i n  i s  u p r e g u l a t e d  i n  m a n y  a m y l o i d  
neurodegenerative diseases and they are found in high 
amounts in amyloid plaques (25), presumably as a result 
of their attempts to prevent protein aggregation. Studies 
in which these chaperone proteins are overexpressed in 
cellular models of amyloidoses will enable an assessment 
of their therapeutic potential in the treatment of such 
diseases.
Conclusions
Whilst often overlooked, the folding and unfolding process 
faced by proteins during their life cycle is not a trivial one. 
Like all biological processes, the folding pathway is tightly 
regulated to ensure proteins reach their correct, functional 
form. However, problems can occur and the number of 
protein conformational diseases that are now recognised is an 
indication of the importance of proteins achieving and 
maintaining their correct fold. That the amyloid fibril 
conformation is potentially accessible to all proteins, no 
matter what their native state, indicates that for many this 
form of toxic protein aggregation is a constant threat. 
Significantly, diseases associated with amyloid fibril 
formation represent some of the western world's most 
debilitating conditions and, since many are associated with 
old age, will become more prevalent over the coming 
decades as the population ages. As such, a greater 
understanding of the mechanism by which fibrils are formed 
and strategies to prevent it are required.
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